Last reviewed · How we verify
Baxdrostat and dapagliflozin
Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, together addressing both hypertension/heart failure and glycemic control.
Baxdrostat inhibits aldosterone synthase to reduce aldosterone production, while dapagliflozin inhibits SGLT2 to increase urinary glucose excretion, together addressing both hypertension/heart failure and glycemic control. Used for Heart failure with reduced ejection fraction, Hypertension with cardiometabolic disease.
At a glance
| Generic name | Baxdrostat and dapagliflozin |
|---|---|
| Also known as | Baxdrostat CIN-107 |
| Sponsor | AstraZeneca |
| Drug class | Aldosterone synthase inhibitor + SGLT2 inhibitor combination |
| Target | CYP11B2 (aldosterone synthase) and SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular, Diabetes |
| Phase | Phase 3 |
Mechanism of action
Baxdrostat is a non-steroidal aldosterone synthase inhibitor that decreases aldosterone levels, reducing sodium retention and blood pressure while improving cardiac function. Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion and has cardioprotective and renoprotective effects. The combination targets complementary pathways in cardiometabolic disease.
Approved indications
- Heart failure with reduced ejection fraction
- Hypertension with cardiometabolic disease
Common side effects
- Hyperkalemia
- Hypotension
- Genital mycotic infections
- Volume depletion
Key clinical trials
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (PHASE3)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. (PHASE2)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin (PHASE3)
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |